Watchlist

Watchlist
ARCA biopharma, Inc. (ABIO)
ARCA biopharma, Inc. (ABIO)
Key events next week - healthcare
Noteworthy events during the week of May 20 - 26 for healthcare investors: More news on: uniQure N.V., Roche Holding Ltd ADR, BioMarin Pharmaceutical Inc., Healthcare stocks news, , Read more …
ARCA Biopharma and Medtronic extend Gencaro clinical trial collaboration agreement
ARCA Biopharma (NASDAQ: ABIO ) announces that Medtronic (NYSE: MDT ) has extended the U.S., Canadian and European Clinical Trial Collaboration Agreement for an additional year to April 2019. More news on: ARCA biopharma, Inc., Medtronic plc, Healthcare stocks news, Stocks on the move, …
ARCA biopharma reports FY results
ARCA biopharma (NASDAQ: ABIO ): FY EPS of -$1.77 More news on: ARCA biopharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …
Arca Biopharma Has One More Shot To Get It Right
Recently, Arca Biopharma ( ABIO ) announced results for its phase 2b trial treating patients with atrial fibrillation (AF) and left ventricular ejection fraction ((HFrEF)). The failed phase 2b trial data caused the stock to tumble by more than 60%. On the outset, the data as a totality of …
3 Things In Biotech You Should Learn Today: February 27, 2018
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Arca Bio crushed on poor heart trial results Company: Arca Bio ( ABIO ) Therapy: Buci…
ARCA biopharma (ABIO) Top-Line Data From Genetic-AF Phase 2B Clinical Trial - Slideshow'
The following slide deck was published by ARCA biopharma, Inc. in conjunction with this Read more …
Your Daily Pharma Scoop: Progenics Update, La Jolla Data, ARCA Biopharma Setback
Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics Pharmaceuticals ( PGNX ), which last week presented at the RBC Capital Markets Global Healthcare Conference. As we have noted before, Progenics has an important upcoming catalyst, which could provide a si…
Midday Gainers / Losers (2/26/2018)
Gainers: NXTD +30% . TAHO +20% . RCM +20% . ZSAN +18% . TTPH +18% . APLS +16% . XTNT +15% . DTRM +14% . CGEN +14% . ACHN +14% . More news on: NXT-ID Inc., Tahoe Resources Inc., R1 RCM Inc., Stocks on the move, , Read more …
Premarket Losers as of 9:05 am (2/26/2018)
ABIO -57% on underwhelming mid-stage Gencaro data. More news on: ARCA biopharma, Inc., Dean Foods Company, TAL Education Group, Stocks on the move, , Read more …
ARCA down 60% premarket on underwhelming mid-stage Gencaro data
Thinly traded nano cap ARCA biopharma (NASDAQ: ABIO ) slumps 60% premarket on increased volume in response to its announcement of results from a Phase 2 clinical trial, GENETIC-AF , evaluating Gencaro (bucindolol hydrochloride) for the the treatment of atrial fibrillation (AF)…
ARCA biopharma, Inc. (ABIO)